These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 29569736)
1. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Modi AA; Nazario HE; Gonzales GR; Gonzalez SA Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736 [TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS; Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342 [TBL] [Abstract][Full Text] [Related]
3. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470 [TBL] [Abstract][Full Text] [Related]
4. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144 [TBL] [Abstract][Full Text] [Related]
5. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562 [TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Abaalkhail F; Elsiesy H; Elbeshbeshy H; Shawkat M; Yousif S; Ullah W; Alabbad S; Al-Jedai A; Ajlan A; Broering D; Saab S; Al Sebayel M; Al-Hamoudi W Transplantation; 2017 Nov; 101(11):2739-2745. PubMed ID: 28795982 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Tao T; Jiang X; Chen Y; Song Y Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142 [TBL] [Abstract][Full Text] [Related]
11. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301 [TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015. Yin S; Barker L; White JZ; Jiles RB J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086 [TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. Sirinawasatien A; Techasirioangkun T PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890 [TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748 [TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906 [TBL] [Abstract][Full Text] [Related]
19. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014 [TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]